Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma

Alessandra Longhi, Michele Macchiagodena, Giovanni Vitali, Gaetano Bacci

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Purpose: To evaluate fertility in male patients with osteosarcoma after chemotherapy including high doses of alkylating agents. Patients and Methods: Postchemotherapy fertility was evaluated in 96 male patients who received chemotherapy at the authors' institution from 1976 to 1996 for localized bone osteosarcoma of the extremities. Four drugs were administrated (doxorubicin, cisplatin, methotrexate, ifosfamide) at different doses according to six different protocols. Eleven patients were prepubertal and 85 were postpubertal at the time of chemotherapy. The median age of these patients at the time of chemotherapy was 17 years (range 10-42), the median age at the time of the interview was 27 years (range 19-53), and the median follow-up from the end of chemotherapy was 9 years (range 4-17). Results: Of the 96 patients, 26 underwent sperm analysis and 20 showed oligo- or azoospermia. Patients who received high-dose ifosfamide showed a higher incidence of azoospermia. Six patients were normospermic and received no ifosfamide or lower doses of ifosfamide. Eight patients fathered a total of 12 children. No birth defects or congenital anomalies were observed in their offspring. Conclusions: The rate of sterility was related to ifosfamide dosage. It appears that pubertal maturation is not affected by chemotherapy. No congenital malformations were seen in the children of the few patients who fathered children.

Original languageEnglish
Pages (from-to)292-296
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume25
Issue number4
DOIs
Publication statusPublished - Apr 2003

Fingerprint

Osteosarcoma
Fertility
Drug Therapy
Ifosfamide
Azoospermia
Oligospermia
Alkylating Agents
Methotrexate
Doxorubicin
Infertility
Cisplatin
Spermatozoa
Extremities
Interviews
Bone and Bones
Incidence

Keywords

  • Chemotherapy
  • High-dose alkylating agents
  • Male fertility
  • Osteosarcoma
  • Pediatrics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. / Longhi, Alessandra; Macchiagodena, Michele; Vitali, Giovanni; Bacci, Gaetano.

In: Journal of Pediatric Hematology/Oncology, Vol. 25, No. 4, 04.2003, p. 292-296.

Research output: Contribution to journalArticle

Longhi, Alessandra ; Macchiagodena, Michele ; Vitali, Giovanni ; Bacci, Gaetano. / Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. In: Journal of Pediatric Hematology/Oncology. 2003 ; Vol. 25, No. 4. pp. 292-296.
@article{3eaac26cc2054a3691300fdfb7c4bffa,
title = "Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma",
abstract = "Purpose: To evaluate fertility in male patients with osteosarcoma after chemotherapy including high doses of alkylating agents. Patients and Methods: Postchemotherapy fertility was evaluated in 96 male patients who received chemotherapy at the authors' institution from 1976 to 1996 for localized bone osteosarcoma of the extremities. Four drugs were administrated (doxorubicin, cisplatin, methotrexate, ifosfamide) at different doses according to six different protocols. Eleven patients were prepubertal and 85 were postpubertal at the time of chemotherapy. The median age of these patients at the time of chemotherapy was 17 years (range 10-42), the median age at the time of the interview was 27 years (range 19-53), and the median follow-up from the end of chemotherapy was 9 years (range 4-17). Results: Of the 96 patients, 26 underwent sperm analysis and 20 showed oligo- or azoospermia. Patients who received high-dose ifosfamide showed a higher incidence of azoospermia. Six patients were normospermic and received no ifosfamide or lower doses of ifosfamide. Eight patients fathered a total of 12 children. No birth defects or congenital anomalies were observed in their offspring. Conclusions: The rate of sterility was related to ifosfamide dosage. It appears that pubertal maturation is not affected by chemotherapy. No congenital malformations were seen in the children of the few patients who fathered children.",
keywords = "Chemotherapy, High-dose alkylating agents, Male fertility, Osteosarcoma, Pediatrics",
author = "Alessandra Longhi and Michele Macchiagodena and Giovanni Vitali and Gaetano Bacci",
year = "2003",
month = "4",
doi = "10.1097/00043426-200304000-00005",
language = "English",
volume = "25",
pages = "292--296",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma

AU - Longhi, Alessandra

AU - Macchiagodena, Michele

AU - Vitali, Giovanni

AU - Bacci, Gaetano

PY - 2003/4

Y1 - 2003/4

N2 - Purpose: To evaluate fertility in male patients with osteosarcoma after chemotherapy including high doses of alkylating agents. Patients and Methods: Postchemotherapy fertility was evaluated in 96 male patients who received chemotherapy at the authors' institution from 1976 to 1996 for localized bone osteosarcoma of the extremities. Four drugs were administrated (doxorubicin, cisplatin, methotrexate, ifosfamide) at different doses according to six different protocols. Eleven patients were prepubertal and 85 were postpubertal at the time of chemotherapy. The median age of these patients at the time of chemotherapy was 17 years (range 10-42), the median age at the time of the interview was 27 years (range 19-53), and the median follow-up from the end of chemotherapy was 9 years (range 4-17). Results: Of the 96 patients, 26 underwent sperm analysis and 20 showed oligo- or azoospermia. Patients who received high-dose ifosfamide showed a higher incidence of azoospermia. Six patients were normospermic and received no ifosfamide or lower doses of ifosfamide. Eight patients fathered a total of 12 children. No birth defects or congenital anomalies were observed in their offspring. Conclusions: The rate of sterility was related to ifosfamide dosage. It appears that pubertal maturation is not affected by chemotherapy. No congenital malformations were seen in the children of the few patients who fathered children.

AB - Purpose: To evaluate fertility in male patients with osteosarcoma after chemotherapy including high doses of alkylating agents. Patients and Methods: Postchemotherapy fertility was evaluated in 96 male patients who received chemotherapy at the authors' institution from 1976 to 1996 for localized bone osteosarcoma of the extremities. Four drugs were administrated (doxorubicin, cisplatin, methotrexate, ifosfamide) at different doses according to six different protocols. Eleven patients were prepubertal and 85 were postpubertal at the time of chemotherapy. The median age of these patients at the time of chemotherapy was 17 years (range 10-42), the median age at the time of the interview was 27 years (range 19-53), and the median follow-up from the end of chemotherapy was 9 years (range 4-17). Results: Of the 96 patients, 26 underwent sperm analysis and 20 showed oligo- or azoospermia. Patients who received high-dose ifosfamide showed a higher incidence of azoospermia. Six patients were normospermic and received no ifosfamide or lower doses of ifosfamide. Eight patients fathered a total of 12 children. No birth defects or congenital anomalies were observed in their offspring. Conclusions: The rate of sterility was related to ifosfamide dosage. It appears that pubertal maturation is not affected by chemotherapy. No congenital malformations were seen in the children of the few patients who fathered children.

KW - Chemotherapy

KW - High-dose alkylating agents

KW - Male fertility

KW - Osteosarcoma

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=0242684432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242684432&partnerID=8YFLogxK

U2 - 10.1097/00043426-200304000-00005

DO - 10.1097/00043426-200304000-00005

M3 - Article

C2 - 12679642

AN - SCOPUS:0242684432

VL - 25

SP - 292

EP - 296

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -